CD274 and hepatocellular carcinoma: As a result, no recommendation can be made for an optimal PD-L1 IHC test in HCC, a tumour where PD-L1 expression predicts for adverse prognosis, but whose predictive role in defining an increased likelihood of response to ICPI remains unclear.6 To address this issue, in Blueprint-HCC we performed a quantitative comparison of five antibody clones used for PD-L1 IHC testing in landmark trials of ICPI.